MGRX Mangoceuticals Inc.

Subscribe to $MGRX

Mangoceuticals Inc.

Subscribe to $MGRX

$MGRX

Misc Health and Biotechnology Services

Health Care

IPO Year: 2023

Exchange: NASDAQ

Recent Analyst Ratings for Mangoceuticals Inc.

Date	Price Target	Rating	Analyst

See more ratings

Mangoceuticals Inc. Press Releases

Fastest customizable press release news feed in the world

View All

Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs

Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company") is issuing the following clarification regarding its press release issued earlier this morning titled "Mangoceuticals Partners with Eli Lilly and Novo Nordisk…". The newly launched Mangoceuticals weight-management programs MangoRx Direct and PeachesRx Direct are licensed and approved to issue, through a third-party provider, valid prescriptions for FDA-approved branded GLP-1 medications, including, when medically appropriate, Zepbound® from Eli Lilly and Wegovy® from Novo Nordisk. These programs allow Mangoceuticals patients to access, for the first time, Eli Lilly and N

11/13/25 7:37:00 PM ET

$MGRX

Misc Health and Biotechnology Services

Health Care

Mangoceuticals Partners with Eli Lilly and Novo Nordisk to Deliver Affordable Access to Zepbound and Wegovy for Obesity Management

Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, is excited to announce that it has launched MangoRx Direct and PeachesRx Direct, two integrated programs that provide direct access to authentic Zepbound® (tirzepatide) from Eli Lilly and Wegovy® (semaglutide) from Novo Nordisk. These branded GLP-1 medications will be made available to both MangoRx and PeachesRx customers via Eli Lilly's LillyDirect® Se

11/13/25 7:00:00 AM ET

$MGRX

Misc Health and Biotechnology Services

Health Care

Mangoceuticals' Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu

Dallas, TX, May 27, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, is excited to share groundbreaking results from field studies based on its patented antiviral compound which it refers to as "MGX-0024". The field studies were conducted by Solice International at Duraiswamy Farm in Palladam, Tamil Nadu, India. These studies, targeting respiratory diseases in chickens, like Newcastle Disease and Chronic Respiratory Disease (

5/27/25 9:00:00 AM ET

$MGRX

Misc Health and Biotechnology Services

Health Care

Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

DALLAS, TX, April 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals Inc. (NASDAQ:MGRX) ("Mangoceuticals" or "MGRX"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, is pleased to announce that it has entered into an Intellectual Property Purchase Agreement to acquire all intellectual property, product formulations, know-how, distribution, supplier relationships and related assets of Smokeless Technology Corp. ("Smokeless Tech"), a Canadian-based pouch innovation company specializing in stimulant and functional pouches. This acquisition marks a strategic expansion into the

4/25/25 9:00:00 AM ET

$MGRX

Misc Health and Biotechnology Services

Health Care

Mangoceuticals Expands into $33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven Diabetinol® in the USA and Canada

Diabetinol® is a clinically supported and patented plant-based nutraceutical product targeting the pre-diabetic and weight loss marketplace DALLAS, TX, March 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that it has entered into a Master Distribution Agreement (the "Agreement") to secure the exclusive licensing and distribution rights for Diabetinol® within the United States and Canada. Diabetinol® is a plant-based nutraceutical clinically supporte

3/25/25 9:00:00 AM ET

$MGRX

Misc Health and Biotechnology Services

Health Care

Mangoceuticals Announces the Launch of "PeachesRx" - a Women's Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments

Dallas, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of men's wellness products via a secure telemedicine platform under the brand MangoRx, proudly announces the official launch of PeachesRx, an innovative women's health and wellness brand focused on providing cutting-edge, convenient treatments tailored to women's unique health needs. These new and innovative women's health and wellness products will be made available via a secure telemedicine platform located at www.PeachesRx.com. PeachesRx will debut with a strong focus on compounded GLP-1 receptor agoni

2/20/25 7:00:00 AM ET

$MGRX

Misc Health and Biotechnology Services

Health Care

Mangoceuticals Advances Antiviral Research on its Patented Respiratory Illness Prevention Technology With New Study Targeting Avian Flu in Poultry Using a Non-Invasive, Non-Pharmaceutical Water-Based Solution

Dallas, Texas, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of innovative health solutions today announced that it is advancing its research into respiratory illness prevention technologies by focusing on finding a practical, everyday solution to combat avian influenza viruses (H5N1), specifically within the poultry industry. The Company has engaged Vipragen Biosciences, an AAALAC-accredited preclinical Contract Research Organization (CRO) based in Mysuru, India ("Vipragen"), to conduct independent efficacy studies aimed at developing an antiviral solution for res

2/12/25 8:00:00 AM ET

$MGRX

Misc Health and Biotechnology Services

Health Care

Mangoceuticals Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 Studies and Engages Vipragen Biosciences to Structure H5N1 Cohort for Expanded Research

Dallas, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of men's wellness products and services via a secure telemedicine platform, today announced significant progress in its ongoing H1N1 efficacy study conducted by Vipragen Biosciences ("Vipragen"), an AAALAC-accredited preclinical CRO in Mysuru, India, on its patented respiratory illness prevention technology in collaboration with Intramont Technologies, Inc. ("Intramont"). Building on strong preliminary results, the Company is advancing to the next stage of research while also engaging Vipragen to structur

2/6/25 7:00:00 AM ET

$MGRX

Misc Health and Biotechnology Services

Health Care

Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation

Dallas, TX & Quebec, Canada, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX), a company focused on developing, marketing, and selling a variety of men's wellness products and services via a secure telemedicine platform, is pleased to announce that it has entered into an exclusive Master Distribution Agreement with Propre Energie, Inc., the developer of skincare brand Dermytol®, a clinically proven treatment designed to improve skin tone and reduce hyperpigmentation. Dermytol® is an advanced, plant-based formula developed to address dark spots, uneven skin tone, acne scars, and other pigmentation concerns. Unlike traditional skin treatments that may cause irritation or

2/3/25 8:30:00 AM ET

$MGRX

Misc Health and Biotechnology Services

Health Care

Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

Dallas, TX, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced the acquisition of patent number WO 2023/086647 PCT/US2022/049857, for mushroom-derived compositions and methods of treatment. This new addition to MangoRx's intellectual property portfolio highlights the Company's commitment to innovative solutions that support holistic health and wellness. The acquired patent encompasses nutraceutical compositions derived from functional mushrooms, including well-known varieties such as Cordyceps sinensi

12/19/24 5:33:00 PM ET

$MGRX

Misc Health and Biotechnology Services

Health Care

Mangoceuticals Inc.

Recent Analyst Ratings for Mangoceuticals Inc.

Mangoceuticals Inc.

Recent Analyst Ratings for Mangoceuticals Inc.

Mangoceuticals Inc. Insider Trading

CFO Johnston Eugene M sold $5,975 worth of shares (5,000 units at $1.20), decreasing direct ownership by 4% to 123,333 units (SEC Form 4)

CFO Johnston Eugene M sold $11,280 worth of shares (10,000 units at $1.13), decreasing direct ownership by 7% to 128,333 units (SEC Form 4)

Director Hamilton Alex P. sold $152,875 worth of shares (125,000 units at $1.22), decreasing direct ownership by 97% to 3,334 units (SEC Form 4)

Chief Executive Officer Cohen Jacob D. was granted 200,000 shares (SEC Form 4)

Director D'Alessio Lorraine Pamela was granted 100,000 shares, increasing direct ownership by 273% to 136,667 units (SEC Form 4)

Chief Financial Officer Johnston Eugene M was granted 100,000 shares, increasing direct ownership by 261% to 138,334 units (SEC Form 4)

Director Myers Kenny was granted 100,000 shares, increasing direct ownership by 273% to 136,667 units (SEC Form 4)

Director Hamilton Alex P. was granted 100,000 shares, increasing direct ownership by 375% to 126,667 units (SEC Form 4)

New insider Isaac Antonios claimed no ownership of stock in the company (SEC Form 3)

Chief Financial Officer Johnston Eugene M was granted 25,000 shares, increasing direct ownership by 187% to 38,334 units (SEC Form 4)

Mangoceuticals Inc. SEC Filings

Mangoceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

SEC Form 144 filed by Mangoceuticals Inc.

SEC Form 10-Q filed by Mangoceuticals Inc.

Amendment: SEC Form 10-Q/A filed by Mangoceuticals Inc.

Mangoceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Mangoceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Mangoceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13D/A filed by Mangoceuticals Inc.

Mangoceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

Mangoceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

Mangoceuticals Inc. Press Releases

Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs

Mangoceuticals Partners with Eli Lilly and Novo Nordisk to Deliver Affordable Access to Zepbound and Wegovy for Obesity Management

Mangoceuticals' Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu

Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

Mangoceuticals Expands into $33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven Diabetinol® in the USA and Canada

Mangoceuticals Announces the Launch of "PeachesRx" - a Women's Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments

Mangoceuticals Advances Antiviral Research on its Patented Respiratory Illness Prevention Technology With New Study Targeting Avian Flu in Poultry Using a Non-Invasive, Non-Pharmaceutical Water-Based Solution

Mangoceuticals Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 Studies and Engages Vipragen Biosciences to Structure H5N1 Cohort for Expanded Research

Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation

Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

Mangoceuticals Inc. Leadership Updates

Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

Mangoceuticals Inc. Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by Mangoceuticals Inc.

SEC Form SC 13D/A filed by Mangoceuticals Inc. (Amendment)

Mangoceuticals Inc. Financials

Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024